Literature DB >> 28719584

Health policy: Me-too drugs with limited benefits - the tale of regorafenib for HCC.

Bishal Gyawali1, Vinay Prasad2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28719584     DOI： 10.1038/nrclinonc.2017.100

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations.

Authors:  A Ruth He; Alec S Goldenberg
Journal:  Therap Adv Gastroenterol       Date:  2013-11       Impact factor: 4.409

2.  Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.

Authors:  Vinay Prasad; Paul R Massey; Tito Fojo
Journal:  J Clin Oncol       Date:  2014-04-07       Impact factor: 44.544

Review 3.  Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?

Authors:  Andrew X Zhu
Journal:  Oncologist       Date:  2006 Jul-Aug

4.  Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials†.

Authors:  B Gyawali; T Shimokata; M Ando; K Honda; Y Ando
Journal:  Ann Oncol       Date:  2017-02-01       Impact factor: 32.976

5.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Jordi Bruix; Shukui Qin; Philippe Merle; Alessandro Granito; Yi-Hsiang Huang; György Bodoky; Marc Pracht; Osamu Yokosuka; Olivier Rosmorduc; Valeriy Breder; René Gerolami; Gianluca Masi; Paul J Ross; Tianqiang Song; Jean-Pierre Bronowicki; Isabelle Ollivier-Hourmand; Masatoshi Kudo; Ann-Lii Cheng; Josep M Llovet; Richard S Finn; Marie-Aude LeBerre; Annette Baumhauer; Gerold Meinhardt; Guohong Han
Journal:  Lancet       Date:  2016-12-06       Impact factor: 79.321

6.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

7.  Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice.

Authors:  I-Cheng Lee; Yi-Tzen Chen; Yee Chao; Teh-Ia Huo; Chung-Pin Li; Chien-Wei Su; Han-Chieh Lin; Fa-Yauh Lee; Yi-Hsiang Huang
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

8.  Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice.

Authors:  Fabien Calcagno; Sabrina Lenoble; Zaher Lakkis; Thierry Nguyen; Samuel Limat; Christophe Borg; Marine Jary; Stefano Kim; Virginie Nerich
Journal:  Clin Med Insights Oncol       Date:  2016-07-04

9.  Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.

Authors:  Hanna K Sanoff; YunKyung Chang; Jennifer L Lund; Bert H O'Neil; Stacie B Dusetzina
Journal:  Oncologist       Date:  2016-05-16
  9 in total
  4 in total

1.  Me too-drugs with limited benefits - the tale of regorafenib for HCC.

Authors:  Bishal Gyawali; Vinay Prasad
Journal:  Nat Rev Clin Oncol       Date:  2017-11-28       Impact factor: 66.675

Review 2.  Systemic Treatment for Advanced Hepatocellular Carcinoma.

Authors:  Mohamed Bouattour; Neil Mehta; Aiwu R He; Emil I Cohen; Jean-Charles Nault
Journal:  Liver Cancer       Date:  2019-03-06       Impact factor: 11.740

3.  Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19.

Authors:  Rahul Banerjee; Vinay Prasad
Journal:  Nat Rev Clin Oncol       Date:  2021-01       Impact factor: 66.675

4.  Sulfarotene, a synthetic retinoid, overcomes stemness and sorafenib resistance of hepatocellular carcinoma via suppressing SOS2-RAS pathway.

Authors:  Feng Qi; Wenxing Qin; Yao Zhang; Yongde Luo; Bing Niu; Quanlin An; Biwei Yang; Keqing Shi; Zhijie Yu; Junwei Chen; Xin Cao; Jinglin Xia
Journal:  J Exp Clin Cancer Res       Date:  2021-09-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.